Skip to main content
SpringerLink
Log in

Apathy and its treatment

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Apathy is a common problem observed in numerous neurologic, psychiatric, and other medical conditions. It is independent from other symptoms and has been associated with a variety of negative outcomes. However, little empirical research has been conducted on potential psychologic or pharmacologic treatments for apathy. The impact of several different medications has been investigated, but very few reports have used well-controlled study designs. At present, agents that potentiate dopamine release and/or delay dopamine reuptake in the central nervous system appear promising for use in apathy. Among these, atypical antipsychotics and methylphenidate have received the greatest attention, and both have been demonstrated to reduce apathy in several patient populations. These findings appear consistent with evidence supporting a role for frontal-subcortical circuitry abnormality in the etiology of apathy. Another class of medication that has been the subject of a larger number of investigations is the acetylcholinesterase inhibitors. These have been reported to reduce apathy in patients with dementia and individuals with traumatic brain injury. Several psychologic interventions have been assessed, largely in geriatric populations, but most have been the subject of only one or a very small number of studies. With this caveat, interventions that have shown promise include participation in discussion groups and cognitive stimulation. Despite some promising findings, further large-scale, well-controlled clinical trials of potentially helpful pharmacologic and psychologic interventions for apathy are essential before any firm recommendations can be made. In the interim, careful evaluation of possible psychosocial and biological contributors to apathy in any given patient is suggested, with treatment planning based accordingly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Marin RS, Wilkosz PA: Disorders of diminished motivation. J Head Trauma Rehab 2005, 20:377–388.

    Google Scholar 

  2. McAllister TW: Apathy. Semin Clin Neuropsychiatry 2000, 5:275–282.

    Article  PubMed  CAS  Google Scholar 

  3. Stuss DT, van Reekum RJMK: Differentiation of states and causes of apathy. In The Neuropsychology of Emotion. Edited by Bor JC. New York: Oxford University Press; 2000:340–363.

    Google Scholar 

  4. Levy R, Dubois B: Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006, 16:916–928.

    Article  PubMed  Google Scholar 

  5. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991, 38:143–162.

    Article  PubMed  CAS  Google Scholar 

  6. Starkstein SE, Petracca G, Chemerinski E, et al.: Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001, 158:872–877.

    PubMed  CAS  Google Scholar 

  7. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308–2314.

    PubMed  CAS  Google Scholar 

  8. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City: College of Medicine, University of Iowa; 1984.

    Google Scholar 

  9. Kirsch-Darrow L, Fernandez HF, Marsiske M, et al.: Dissociating apathy and depression in Parkinson disease. Neurology 2006, 67:33–38.

    Article  PubMed  CAS  Google Scholar 

  10. Kiang M, Christensen BK, Remington G, et al.: Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr Res 2003, 63:79–88.

    Article  PubMed  Google Scholar 

  11. van Reekum R, Stuss DT, Ostrander L: Apathy: why care? J Neuropsychiatry Clin Neurosci 2005, 17:7–19.

    PubMed  Google Scholar 

  12. Paul RH, Brickman AM, Navia B, et al.: Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 2005, 17:167–171.

    PubMed  Google Scholar 

  13. Roth RM, Flashman LA, Saykin AJ, et al.: Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits. Am J Psychiatry 2004, 161:157–159.

    Article  PubMed  Google Scholar 

  14. Rosen HJ, Allison SC, Schauer GF, et al.: Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005, 128:2612–2625.

    Article  PubMed  Google Scholar 

  15. Baudic S, Maison P, Dolbeau G, et al.: Cognitive impairment related to apathy in early Huntington’s disease. Dement Geriatr Cogn Disord 2006, 21:316–321.

    Article  PubMed  Google Scholar 

  16. McPherson S, Fairbanks L, Tiken S, et al.: Apathy and executive function in Alzheimer’s disease. J Int Neuropsychol Soc 2002, 8:373–381.

    Article  PubMed  Google Scholar 

  17. Barnhart WJ, Makela EH, Latocha MJ: SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract 2004, 10:196–199.

    Article  PubMed  Google Scholar 

  18. Chatterjee A, Fahn S: Methylphenidate treats apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2002, 14:461–462.

    PubMed  Google Scholar 

  19. Keenan S, Mavaddat N, Iddon J, et al.: Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review. Br J Neurosurg 2005, 19:46–50.

    Article  PubMed  CAS  Google Scholar 

  20. Jansen IH, Olde Rikkert MG, Hulsbos HA, et al.: Toward individualized evidence-based medicine: five “N of 1” trials of methylphenidate in geriatric patients. J Am Geriatr Soc 2001, 49:474–476.

    Article  PubMed  CAS  Google Scholar 

  21. Padala PR, Petty F, Bhatia SC: Methylphenidate may treat apathy independent of depression. Ann Pharmacother 2005, 39:1947–1949.

    Article  PubMed  Google Scholar 

  22. Padala PR, Burke WJ, Bhatia SC, et al.: Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci 2007, 19:81–83.

    PubMed  CAS  Google Scholar 

  23. Van Reekum R, Bayley M, Garner S, et al.: N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995, 9:49–53.

    Article  PubMed  Google Scholar 

  24. Kraus MF, Maki PM: Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997, 9:222–230.

    PubMed  CAS  Google Scholar 

  25. Marin RS, Fogel BS, Hawkins J, et al.: Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995, 7:23–30.

    PubMed  CAS  Google Scholar 

  26. Debette S, Kozlowski O, Steinling M, et al.: Levodopa and bromocriptine in hypoxic brain injury. J Neurol 2002, 249:1678–1682.

    Article  PubMed  CAS  Google Scholar 

  27. Czernecki V, Pillon B, Houeto JL, et al.: Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia 2002, 40:2257–2267.

    Article  PubMed  CAS  Google Scholar 

  28. Newburn G, Newburn D: Selegiline in the management of apathy following traumatic brain injury. Brain Inj 2005, 19:149–154.

    Article  PubMed  Google Scholar 

  29. Corcoran C, Wong ML, O’Keane V: Bupropion in the management of apathy. J Psychopharmacol 2004, 18:133–135.

    Article  PubMed  CAS  Google Scholar 

  30. Gauthier S, Feldman H, Hecker J, et al.: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002, 14:389–404.

    Article  PubMed  Google Scholar 

  31. Masanic CA, Bayley MT, VanReekum R, et al.: Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil 2001, 7:896–901.

    Article  Google Scholar 

  32. Brodaty H, Woodward M, Boundy K, et al.: Anaturalistic study of galantamine for Alzheimer’s disease. CNS Drugs 2006, 20:935–943.

    Article  PubMed  CAS  Google Scholar 

  33. Arnold DS, Rosse RB, Dickinson D, et al.: Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient. J Clin Psychiatry 2004, 65:1723–1724.

    Article  PubMed  Google Scholar 

  34. Edwards KR, Hershey L, Wray L, et al.: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord 2004, 17(Suppl 1):40–48.

    Article  PubMed  CAS  Google Scholar 

  35. Cummings JL, Koumaras B, Chen M, et al.: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005, 3:137–148.

    Article  PubMed  CAS  Google Scholar 

  36. McKeith IG, Grace JB, Walker Z, et al.: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000, 15:387–392.

    Article  PubMed  CAS  Google Scholar 

  37. Alvarez E, Ciudad A, Olivares JM, et al.: A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 2006, 26:238–249.

    Article  PubMed  CAS  Google Scholar 

  38. Marangell LB, Johnson CR, Kertz B, et al.: Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 2002, 63:391–395.

    PubMed  CAS  Google Scholar 

  39. Negrón AE, Reichman WE: Risperidone in the treatment of patients with Alzheimer’s disease with negative symptoms. Int Psychogeriatr 2000, 12:527–536.

    Article  PubMed  Google Scholar 

  40. Politis AM, Vozzella S, Mayer LS, et al.: A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004, 19:1087–1094.

    Article  PubMed  Google Scholar 

  41. Chapman SB, Weiner MF, Rackley A, et al.: Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004, 47:1149–1163.

    Article  PubMed  Google Scholar 

  42. Verkaik R, van Weert JC, Francke AL: The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005, 20:301–314.

    Article  PubMed  Google Scholar 

  43. Finnema E, Droes RM, Ettema T, et al.: The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: a randomized clinical trial. Int J Geriatr Psychiatry 2005, 20:330–343.

    Article  PubMed  Google Scholar 

  44. Kragt K, Holtkamp CCM, Dongen MCJM, et al.: [The effect of snoezelen in the sensory stimulation room on the well-being of demented elderly. A cross-over trial in residents of the R.C. Care Center Bernardus in Amsterdam]. Verpleegkunde 1997, 12:227–236.

    PubMed  CAS  Google Scholar 

  45. Hopman-Rock M, Staats PGM, Tak ECPM, et al.: The effects of a psychomotor activation program for use in groups of cognitively impaired people in homes for the elderly. Int J Geriatr Psychiatry 1999, 14:633–642.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA

    Laura A. Flashman PhD

Authors
  1. Robert M. Roth PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura A. Flashman PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas W. McAllister MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura A. Flashman PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roth, R.M., Flashman, L.A. & McAllister, T.W. Apathy and its treatment. Curr Treat Options Neurol 9, 363–370 (2007). https://doi.org/10.1007/s11940-007-0022-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-007-0022-5

Keywords

Search

Navigation